Fisher Asset Management LLC Has $7.14 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Fisher Asset Management LLC lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 451,655 shares of the biotechnology company’s stock after selling 31,598 shares during the quarter. Fisher Asset Management LLC owned approximately 0.33% of Arrowhead Pharmaceuticals worth $7,136,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. XTX Topco Ltd bought a new stake in Arrowhead Pharmaceuticals during the first quarter worth $133,000. Vanguard Group Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock worth $168,201,000 after purchasing an additional 1,018,273 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 1.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,035,290 shares of the biotechnology company’s stock valued at $13,190,000 after purchasing an additional 17,570 shares during the period. Ontario Teachers Pension Plan Board acquired a new stake in Arrowhead Pharmaceuticals in the 1st quarter valued at about $583,000. Finally, Maryland State Retirement & Pension System bought a new position in Arrowhead Pharmaceuticals during the first quarter worth about $471,000. 62.61% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ARWR has been the topic of several research analyst reports. Piper Sandler upped their price objective on Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Bank of America increased their price target on Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the company a “buy” rating in a research note on Monday. HC Wainwright lifted their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Tuesday. Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday. Finally, Royal Bank Of Canada raised their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.33.

Arrowhead Pharmaceuticals Trading Down 0.6%

NASDAQ ARWR opened at $64.66 on Friday. The firm has a market capitalization of $8.78 billion, a PE ratio of -808.15 and a beta of 1.28. The business’s 50-day moving average price is $41.44 and its two-hundred day moving average price is $27.16. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $67.14.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Mauro Ferrari sold 8,750 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $56.39, for a total value of $493,412.50. Following the transaction, the director owned 68,764 shares in the company, valued at approximately $3,877,601.96. The trade was a 11.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James C. Hamilton sold 20,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider owned 212,122 shares of the company’s stock, valued at approximately $7,424,270. This trade represents a 8.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 43,750 shares of company stock valued at $1,643,413. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.